Related Experiment Video

Updated: Jul 11, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Selinexor: Changing the paradigm in patients with TP53 wild-type endometrial cancer?

Mohamed A Gouda1, Kyaw Z Thein2

  • 1Department of Investigational Cancer Therapeutics (A Phase I Program),The University of Texas M.D. Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA.

Med (New York, N.Y.)
|November 11, 2023
PubMed

Insights

Recurrent endometrial cancer (EC) is difficult to treat. The SIENDO trial found selinexor may benefit patients with TP53 wild-type advanced or recurrent EC, offering new hope.

Area of Science:

  • Oncology
  • Gynecologic Oncology
  • Cancer Therapeutics

Background:

  • Recurrent endometrial cancer (EC) presents significant treatment challenges.
  • Despite advances in personalized medicine, effective therapies for recurrent EC remain limited.
  • Identifying novel therapeutic strategies is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the clinical benefit of selinexor in patients with advanced or recurrent endometrial cancer.
  • To assess the efficacy of selinexor specifically in the TP53 wild-type subgroup of EC patients.

Main Methods:

  • The study analyzed data from the SIENDO trial.
  • Patient population included those with advanced or recurrent endometrial cancer.
  • Focus was on patients with TP53 wild-type tumors.

Main Results:

  • The SIENDO trial demonstrated a potential clinical benefit of selinexor.
  • Selinexor showed promise in patients with TP53 wild-type advanced/recurrent EC.
  • These findings suggest a potential new treatment avenue.

Conclusions:

  • Selinexor may offer a therapeutic option for a specific subset of EC patients.
  • Further research is warranted to explore selinexor's role in EC treatment.
  • The quest for novel therapies in recurrent EC continues.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

14.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K